Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel (ANTARCTIC)
The ANTARCTIC Study - Assessment of a Normal Versus Tailored Dose of Prasugrel After Stenting in Patients Aged > 75 Years to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Nimes, France, 30029
- CHU Caremeau à Nimes - Service de Cardiologie
-
Paris, France, 75013
- ACTION study group - Institut de Cardiologie- Hôpital la Pitié Salpêtrière
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute coronary syndrome (STEMI and NSTEMI) treated by PCI
- Stent (bare metal stent or drug eluting stent) regardless of the regime of thienopyridines administered before randomisation
- Age ≥ 75 years.
- Aspirin dose of 75 mg will be recommended but study authorizes doses ranging from 75-160 mg
- Ability to understand and to comply with the study protocol.
- Written informed consent
Exclusion Criteria:
- Prior history of ischemic or hemorrhagic stroke or transient ischemic attack, or sub-arachnoids haemorrhage
- Have received fibrinolytic therapy within 48 hours of entry or randomisation into the study
- Are receiving vitamin K antagonist
- Concomitant medical illness (terminal malignancy) that is associated with reduced survival over the expected study treatment period.
- History of intolerance or allergy to ASA or approved thienopyridines (ticlopidine, clopidogrel, or prasugrel)
- Have active pathological bleeding or history of bleeding diathesis
- Thrombocytopenia < 100 000 µL
- Severe hepatic impairment (Child Pugh class C).
- Have a condition associated with poor treatment compliance, including dementia or mental illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1: Monitoring Arm
Monitoring Arm: dose adjustment of prasugrel with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low responders
|
Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
|
|
Active Comparator: 2: Conventional Arm
Conventional Arm: fixed dose of prasugrel 5 mg
|
fixed dose of prasugrel 5 mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite of Cardiovascular death, myocardial infarction, stroke, urgent revascularisation, stent thrombosis and bleedings according to the BARC definitions (type 2, 3 or 5) through 12 months of randomisation
Time Frame: through 12 months of randomisation
|
Composite of Cardiovascular death, myocardial infarction, stroke, urgent revascularisation, stent thrombosis and bleedings according to the BARC definitions (type 2, 3 or 5) through 12 months of randomisation
|
through 12 months of randomisation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the benefice of prasugrel adjustment on the composite ischemic endpoint of cardiovascular (CV) death, MI, definite stent thrombosis and Urgent revascularisation through 12 months of randomisation
Time Frame: through 12 months of randomisation
|
The key secondary objective is to evaluate the benefice of prasugrel adjustment on the composite ischemic endpoint of cardiovascular (CV) death, MI, definite stent thrombosis and Urgent revascularisation through 12 months of randomisation
|
through 12 months of randomisation
|
|
CV death, MI, stroke through 12 months of randomisation
Time Frame: through 12 months of randomisation
|
through 12 months of randomisation
|
|
|
CV death, MI, stroke or Urgent Revascularization through 12 months of randomisation
Time Frame: through 12 months of randomisation
|
through 12 months of randomisation
|
|
|
CV death: any death
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
Any death or resuscitated cardiac death
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
CV death or MI
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
Definite stent thrombosis (ARC definition)
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
All types of bleeding according to the BARC definitions 1, 2, 3, 4, 5
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
BARC Bleeding of type 2, 3 or 5
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
Bleeding TIMI major through 12 months of randomisation
Time Frame: through 12 months of randomisation
|
through 12 months of randomisation
|
|
|
GUSTO severe or moderate bleeding
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
STEEPLE bleeding definitions (major, minor or both)
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
ISTH bleeding definitions (major and clinically relevant non major)
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
Bleeding TIMI minor
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
Bleeding TIMI minimal
Time Frame: 12 months after randomization
|
12 months after randomization
|
|
|
Bleeding TIMI major, minor and combination
Time Frame: 12 months after randomization
|
12 months after randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Gilles MONTALESCOT, MD,PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
General Publications
- Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, Carrie D, Belle L, Souteyrand G, Aubry P, Sabouret P, du Fretay XH, Beygui F, Bonnet JL, Lattuca B, Pouillot C, Varenne O, Boueri Z, Van Belle E, Henry P, Motreff P, Elhadad S, Salem JE, Abtan J, Rousseau H, Collet JP, Vicaut E, Montalescot G; ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016 Oct 22;388(10055):2015-2022. doi: 10.1016/S0140-6736(16)31323-X. Epub 2016 Aug 28.
- Lattuca B, Cayla G, Silvain J, Cuisset T, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, El Mahmoud R, Carrie D, Souteyrand G, Kerneis M, Hauguel-Moreau M, Zeitouni M, Guedeney P, Diallo A, Collet JP, Vicaut E, Montalescot G; ACTION Study Group. Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. Am J Cardiovasc Drugs. 2021 Nov;21(6):681-691. doi: 10.1007/s40256-021-00468-8. Epub 2021 Jun 30.
- Cayla G, Cuisset T, Silvain J, Henry P, Leclercq F, Carrie D, Etienne CS, Belle L, Range G, Pouillot C, Varenne O, Van Belle E, Boueri Z, Motreff P, Elhadad S, Delarche N, El Mahmoud R, Vicaut E, Collet JP, Montalescot G; ANTARCTIC investigators. Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. Am Heart J. 2014 Nov;168(5):674-81. doi: 10.1016/j.ahj.2014.07.026. Epub 2014 Aug 7.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Acute Coronary Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Clopidogrel
- Prasugrel Hydrochloride
Other Study ID Numbers
Other Study ID Numbers
- P110101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.